Close

Gilead Sciences (GILD) and MacroGenics (MGNX) Announce Oncology Collaboration to Develop Bispecific Antibodies Oct 17, 2022 07:32AM
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies Oct 17, 2022 07:30AM
I-Mab Biopharma (IMAB) Announces IND Approval from China NMPA for Phase 2 Trial of Enoblituzumab Dec 27, 2021 08:03AM
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors Dec 27, 2021 08:00AM
I-Mab Biopharma (IMAB) Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors Sep 28, 2021 08:02AM


Sep 28, 2021 08:00AM I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Jun 16, 2021 07:33AM Zai Lab (ZLAB) and MacroGenics (MGNX) Enter Pact to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:31AM Macrogenics (MGNX), Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:30AM MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:30AM MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:30AM Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Jun 16, 2021 07:30AM Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Dec 16, 2020 08:15PM Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Dec 16, 2020 08:15PM Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Nov 30, 2020 04:30PM MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
Nov 30, 2020 04:30PM MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
Oct 29, 2019 07:05PM Notice of Lead Plaintiff Deadline for Shareholders in the Macrogenics, Inc. Securities Class Action Lawsuit
Oct 25, 2017 06:49AM Incyte (INCY) and MacroGenics (MGNX) Enter Pact on Anti-PD-1 Monoclonal Antibody MGA012
Oct 25, 2017 06:45AM Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
Oct 22, 2015 07:30AM MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer
Aug 14, 2014 10:15AM Griffin's Blue Ridge Capital 13F Shows New MasterCard (MA), Visa (V) Stakes (more...)
May 15, 2014 10:29AM Griffin's Blue Ridge Capital Shows New Stakes in Allegion (ALLE), Castlight Health (CSLT), Myriad Genetics (MYGN), Walgreen (WAG) (more...)
Feb 14, 2014 02:07PM Blue Ridge Capital Enters Apple (AAPL), Twitter (TWTR) (more...)